Mariner
MLYS icon

Mariner’s Mineralys Therapeutics MLYS Stock Holding History

Mariner’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Buy
+12,678
New +$348K ﹤0.01% 2739
2026
Q1 		– Sell
-10,230
Closed -$371K – 3722
2025
Q4 		$371K Sell
10,230
-6,179
-38% -$248K ﹤0.01% 2669
2025
Q3 		$622K Sell
16,409
-12,295
-43% -$266K ﹤0.01% 2258
2025
Q2 		$388K Buy
+28,704
New +$416K ﹤0.01% 2524

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mariner's MLYS Position: Q2 2026 in Review

Mariner opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 12,678 shares worth $342K. The stake represents ﹤0.01% of the portfolio and ranks #2739 among its holdings. This is a return to the name: Mariner previously reported a position in MLYS as recently as Q4 2025.

Mariner first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $622K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Mariner held 12,678 shares of Mineralys Therapeutics worth $342K as of Q2 2026.
  • Mineralys Therapeutics was a new Mariner position in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2739 holding.
  • Mariner first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Mariner's Mineralys Therapeutics position peaked at $622K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.